Shenzhen Salubris Pharmaceuticals (SHE:002294) said China's drug regulator accepted its clinical trial application for SAL0195.
The drug targets lipid-related diseases, according to a Friday filing with the Shenzhen bourse.
Shares of the pharmaceutical company were down 2% in recent trade.